With the restructuring measures taken in 2009, Evotec has significantly reduced its cost base going forward. The impact of Evotec's SG&A savings will be fully reflected in the Company's financial results for the years 2010 and beyond. In addition, Evotec expects research & development (R&D) expenses to decrease considerably from 2009 levels. The Company will focus on key programmes and targets to invest approximately EUR 10 m in R&D in 2010. As a result, Evotec's Group operating result before impairment is expected to improve significantly over 2009.